SCHEMBL5136167

SCHEMBL5136167

CCCCn1c(CN(Cc2ccc(C(=O)OC)cc2)Cc2ccc(O)cc2Cl)cnc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 17/20 0.43
AGTR2 P50052 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136085 0.90 AGTR1 (0.45) AGTR1AGTR2
SCHEMBL5135509 0.90 TSHR (0.38)
SCHEMBL5135873 0.88 TSHR (0.35) AGTR1
SCHEMBL5134636 0.88 AGTR1 (0.46) AGTR1AGTR2
SCHEMBL5135023 0.84 AGTR1 (0.45) AGTR1AGTR2
SCHEMBL5135175 0.84 AGTR1 (0.43) AGTR1AGTR2
SCHEMBL14415666 0.84 TSHR (0.33)
SCHEMBL4770835 0.83 TSHR (0.39)
SCHEMBL5137587 0.83 PDK1 (0.36)
SCHEMBL5136526 0.82 C5AR1 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed